Casas, JP;
Hingorani, AD;
(2012)
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.
Lancet
, 379
(9822)
1214 - 1224.
10.1016/S0140-6736(12)60110-X.
Preview |
PDF
1346393.pdf Download (329kB) |
Abstract
A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown.
Archive Staff Only
View Item |